HC Wainwright Forecasts Weaker Earnings for Xeris Biopharma

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) – Investment analysts at HC Wainwright lowered their FY2027 earnings estimates for shares of Xeris Biopharma in a note issued to investors on Monday, November 11th. HC Wainwright analyst O. Livnat now forecasts that the company will post earnings per share of $0.19 for the year, down from their previous estimate of $0.27. HC Wainwright currently has a “Buy” rating and a $6.60 target price on the stock. The consensus estimate for Xeris Biopharma’s current full-year earnings is ($0.40) per share.

Separately, Piper Sandler downgraded shares of Xeris Biopharma from an “overweight” rating to a “neutral” rating and set a $3.00 price target for the company. in a report on Monday.

Xeris Biopharma Stock Performance

XERS stock opened at $3.28 on Tuesday. Xeris Biopharma has a one year low of $1.46 and a one year high of $3.64. The stock has a market capitalization of $488.72 million, a PE ratio of -7.29 and a beta of 2.70. The company has a fifty day moving average of $2.97 and a 200-day moving average of $2.51.

Hedge Funds Weigh In On Xeris Biopharma

Hedge funds have recently added to or reduced their stakes in the business. Simplicity Wealth LLC purchased a new position in Xeris Biopharma during the 2nd quarter valued at about $27,000. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Xeris Biopharma in the third quarter worth approximately $35,000. Allspring Global Investments Holdings LLC boosted its position in shares of Xeris Biopharma by 4,512.5% in the second quarter. Allspring Global Investments Holdings LLC now owns 16,282 shares of the company’s stock worth $37,000 after acquiring an additional 15,929 shares during the last quarter. Bayesian Capital Management LP acquired a new stake in shares of Xeris Biopharma in the first quarter worth approximately $37,000. Finally, Asset Management Group Inc. boosted its position in shares of Xeris Biopharma by 130.7% in the second quarter. Asset Management Group Inc. now owns 26,480 shares of the company’s stock worth $60,000 after acquiring an additional 15,000 shares during the last quarter. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.